Copenhagen and Oslo, 18th March 2011, 2011-03-18 11:02 CET (GLOBE NEWSWIRE) -- Affitech A/S (NASDAQ OMX: AFFI) announced today that one of the Company’s Norwegian investors Ferd AS have received 3.281.375 shares in Affitech due to the fact that the investment fund Teknoinvest VII KS has been dissolved. Ferd AS was a limited partner (investor) in Teknoinvest VII KS. Ferd AS total holding after this transaction is 39.296.847 shares equal to 8,06% of the total outstanding shares. Ferd AS is represented in Affitechs Board of Directors by Pål Rødseth.
About Affitech
Affitech AS is a publicly traded (NASDAQ OMX Copenhagen) human therapeutic antibody company based in Copenhagen, Denmark with R&D facilities in Oslo, Norway. The company utilizes a range of proprietary antibody technologies for the discovery of fully human antibodies for application in oncology, inflammation and other disease areas. CBAS™ (Cell Based Antibody Selection) is Affitech’s premier discovery engine for the isolation of lead antibodies to cell surface molecules in situ. Several of the Company's proprietary product candidates were generated by CBAS™. Further information is available at www.affitech.com.
For more information please contact
Randi Krogsgaard, Director IR & Communications
Tel # +45 2320 1001, e-mail: ir@affitech.com